Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Modular Dose Escalation With Cohort Expansion of CP-506 (HAP) in Patients With Solid Tumor Types With High Incidence of HRD/FAD in Monotherapy or With Carboplatin or Patients With Solid Tumour and OPD Receiving ICI

Next Previous
X
Search
Trial Profile

Phase 1/2 Modular Dose Escalation With Cohort Expansion of CP-506 (HAP) in Patients With Solid Tumor Types With High Incidence of HRD/FAD in Monotherapy or With Carboplatin or Patients With Solid Tumour and OPD Receiving ICI

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Avelumab (Primary) ; Carboplatin (Primary) ; Cemiplimab (Primary) ; CP-506 (Primary) ; Durvalumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Head and neck cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 27 Apr 2023 Status changed from not yet recruiting to recruiting.
    • 14 Mar 2023 Planned initiation date changed from 1 Oct 2022 to 1 Apr 2023.
    • 23 Jun 2022 Planned End Date changed from 1 Oct 2025 to 1 May 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top